Report cover image

Tumor Necrosis Factor (TNF) Antagonists Industry Research Report 2025

Publisher APO Research, Inc.
Published Jul 07, 2025
Length 135 Pages
SKU # APRC20261336

Description

Summary

According to APO Research, the global Tumor Necrosis Factor (TNF) Antagonists market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Tumor Necrosis Factor (TNF) Antagonists is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Tumor Necrosis Factor (TNF) Antagonists is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Tumor Necrosis Factor (TNF) Antagonists is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Tumor Necrosis Factor (TNF) Antagonists include Yuxi Jiahe Biotechnology, Taizhou Maiboteike Pharmaceuticals, Hangzhou Bozhirui Biopharmaceuticals, UCB, Torrent Pharmaceuticals, Pfizer, Nippon Kayaku, Nichiiko and Johnson & Johnson, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Tumor Necrosis Factor (TNF) Antagonists, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor Necrosis Factor (TNF) Antagonists.

The report will help the Tumor Necrosis Factor (TNF) Antagonists manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.



The Tumor Necrosis Factor (TNF) Antagonists market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Tumor Necrosis Factor (TNF) Antagonists market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Tumor Necrosis Factor (TNF) Antagonists Segment by Company

Yuxi Jiahe Biotechnology
Taizhou Maiboteike Pharmaceuticals
Hangzhou Bozhirui Biopharmaceuticals
UCB
Torrent Pharmaceuticals
Pfizer
Nippon Kayaku
Nichiiko
Johnson & Johnson
Eisai
Celltrion
Cadila Healthcare
Boehringer Ingelheim
Amgen
AbbVie
Tumor Necrosis Factor (TNF) Antagonists Segment by Type

Adalimumab
Golimumab
Becelizumab
Etanercept
Infliximab
Tumor Necrosis Factor (TNF) Antagonists Segment by Application

Hospital
Clinic
Other
Tumor Necrosis Factor (TNF) Antagonists Segment by Region


North America
United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Colombia
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Necrosis Factor (TNF) Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tumor Necrosis Factor (TNF) Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Necrosis Factor (TNF) Antagonists.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Tumor Necrosis Factor (TNF) Antagonists manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Tumor Necrosis Factor (TNF) Antagonists by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Tumor Necrosis Factor (TNF) Antagonists in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

135 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Tumor Necrosis Factor (TNF) Antagonists Market Size (2020-2031)
2.2.2 Global Tumor Necrosis Factor (TNF) Antagonists Sales (2020-2031)
2.2.3 Global Tumor Necrosis Factor (TNF) Antagonists Market Average Price (2020-2031)
2.3 Tumor Necrosis Factor (TNF) Antagonists by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Adalimumab
2.3.3 Golimumab
2.3.4 Becelizumab
2.3.5 Etanercept
2.3.6 Infliximab
2.4 Tumor Necrosis Factor (TNF) Antagonists by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Hospital
2.4.3 Clinic
2.4.4 Other
3 Market Competitive Landscape by Manufacturers
3.1 Global Tumor Necrosis Factor (TNF) Antagonists Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Tumor Necrosis Factor (TNF) Antagonists Sales (K Units) of Manufacturers (2020-2025)
3.3 Global Tumor Necrosis Factor (TNF) Antagonists Revenue of Manufacturers (2020-2025)
3.4 Global Tumor Necrosis Factor (TNF) Antagonists Average Price by Manufacturers (2020-2025)
3.5 Global Tumor Necrosis Factor (TNF) Antagonists Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Tumor Necrosis Factor (TNF) Antagonists, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Tumor Necrosis Factor (TNF) Antagonists, Product Type & Application
3.8 Global Manufacturers of Tumor Necrosis Factor (TNF) Antagonists, Established Date
3.9 Global Tumor Necrosis Factor (TNF) Antagonists Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Yuxi Jiahe Biotechnology
4.1.1 Yuxi Jiahe Biotechnology Company Information
4.1.2 Yuxi Jiahe Biotechnology Business Overview
4.1.3 Yuxi Jiahe Biotechnology Tumor Necrosis Factor (TNF) Antagonists Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Yuxi Jiahe Biotechnology Tumor Necrosis Factor (TNF) Antagonists Product Portfolio
4.1.5 Yuxi Jiahe Biotechnology Recent Developments
4.2 Taizhou Maiboteike Pharmaceuticals
4.2.1 Taizhou Maiboteike Pharmaceuticals Company Information
4.2.2 Taizhou Maiboteike Pharmaceuticals Business Overview
4.2.3 Taizhou Maiboteike Pharmaceuticals Tumor Necrosis Factor (TNF) Antagonists Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Taizhou Maiboteike Pharmaceuticals Tumor Necrosis Factor (TNF) Antagonists Product Portfolio
4.2.5 Taizhou Maiboteike Pharmaceuticals Recent Developments
4.3 Hangzhou Bozhirui Biopharmaceuticals
4.3.1 Hangzhou Bozhirui Biopharmaceuticals Company Information
4.3.2 Hangzhou Bozhirui Biopharmaceuticals Business Overview
4.3.3 Hangzhou Bozhirui Biopharmaceuticals Tumor Necrosis Factor (TNF) Antagonists Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Hangzhou Bozhirui Biopharmaceuticals Tumor Necrosis Factor (TNF) Antagonists Product Portfolio
4.3.5 Hangzhou Bozhirui Biopharmaceuticals Recent Developments
4.4 UCB
4.4.1 UCB Company Information
4.4.2 UCB Business Overview
4.4.3 UCB Tumor Necrosis Factor (TNF) Antagonists Sales, Revenue and Gross Margin (2020-2025)
4.4.4 UCB Tumor Necrosis Factor (TNF) Antagonists Product Portfolio
4.4.5 UCB Recent Developments
4.5 Torrent Pharmaceuticals
4.5.1 Torrent Pharmaceuticals Company Information
4.5.2 Torrent Pharmaceuticals Business Overview
4.5.3 Torrent Pharmaceuticals Tumor Necrosis Factor (TNF) Antagonists Sales, Revenue and Gross Margin (2020-2025)
4.5.4 Torrent Pharmaceuticals Tumor Necrosis Factor (TNF) Antagonists Product Portfolio
4.5.5 Torrent Pharmaceuticals Recent Developments
4.6 Pfizer
4.6.1 Pfizer Company Information
4.6.2 Pfizer Business Overview
4.6.3 Pfizer Tumor Necrosis Factor (TNF) Antagonists Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Pfizer Tumor Necrosis Factor (TNF) Antagonists Product Portfolio
4.6.5 Pfizer Recent Developments
4.7 Nippon Kayaku
4.7.1 Nippon Kayaku Company Information
4.7.2 Nippon Kayaku Business Overview
4.7.3 Nippon Kayaku Tumor Necrosis Factor (TNF) Antagonists Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Nippon Kayaku Tumor Necrosis Factor (TNF) Antagonists Product Portfolio
4.7.5 Nippon Kayaku Recent Developments
4.8 Nichiiko
4.8.1 Nichiiko Company Information
4.8.2 Nichiiko Business Overview
4.8.3 Nichiiko Tumor Necrosis Factor (TNF) Antagonists Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Nichiiko Tumor Necrosis Factor (TNF) Antagonists Product Portfolio
4.8.5 Nichiiko Recent Developments
4.9 Johnson & Johnson
4.9.1 Johnson & Johnson Company Information
4.9.2 Johnson & Johnson Business Overview
4.9.3 Johnson & Johnson Tumor Necrosis Factor (TNF) Antagonists Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Johnson & Johnson Tumor Necrosis Factor (TNF) Antagonists Product Portfolio
4.9.5 Johnson & Johnson Recent Developments
4.10 Eisai
4.10.1 Eisai Company Information
4.10.2 Eisai Business Overview
4.10.3 Eisai Tumor Necrosis Factor (TNF) Antagonists Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Eisai Tumor Necrosis Factor (TNF) Antagonists Product Portfolio
4.10.5 Eisai Recent Developments
4.11 Celltrion
4.11.1 Celltrion Company Information
4.11.2 Celltrion Business Overview
4.11.3 Celltrion Tumor Necrosis Factor (TNF) Antagonists Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Celltrion Tumor Necrosis Factor (TNF) Antagonists Product Portfolio
4.11.5 Celltrion Recent Developments
4.12 Cadila Healthcare
4.12.1 Cadila Healthcare Company Information
4.12.2 Cadila Healthcare Business Overview
4.12.3 Cadila Healthcare Tumor Necrosis Factor (TNF) Antagonists Sales, Revenue and Gross Margin (2020-2025)
4.12.4 Cadila Healthcare Tumor Necrosis Factor (TNF) Antagonists Product Portfolio
4.12.5 Cadila Healthcare Recent Developments
4.13 Boehringer Ingelheim
4.13.1 Boehringer Ingelheim Company Information
4.13.2 Boehringer Ingelheim Business Overview
4.13.3 Boehringer Ingelheim Tumor Necrosis Factor (TNF) Antagonists Sales, Revenue and Gross Margin (2020-2025)
4.13.4 Boehringer Ingelheim Tumor Necrosis Factor (TNF) Antagonists Product Portfolio
4.13.5 Boehringer Ingelheim Recent Developments
4.14 Amgen
4.14.1 Amgen Company Information
4.14.2 Amgen Business Overview
4.14.3 Amgen Tumor Necrosis Factor (TNF) Antagonists Sales, Revenue and Gross Margin (2020-2025)
4.14.4 Amgen Tumor Necrosis Factor (TNF) Antagonists Product Portfolio
4.14.5 Amgen Recent Developments
4.15 AbbVie
4.15.1 AbbVie Company Information
4.15.2 AbbVie Business Overview
4.15.3 AbbVie Tumor Necrosis Factor (TNF) Antagonists Sales, Revenue and Gross Margin (2020-2025)
4.15.4 AbbVie Tumor Necrosis Factor (TNF) Antagonists Product Portfolio
4.15.5 AbbVie Recent Developments
5 Global Tumor Necrosis Factor (TNF) Antagonists Market Scenario by Region
5.1 Global Tumor Necrosis Factor (TNF) Antagonists Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Tumor Necrosis Factor (TNF) Antagonists Sales by Region: 2020-2031
5.2.1 Global Tumor Necrosis Factor (TNF) Antagonists Sales by Region: 2020-2025
5.2.2 Global Tumor Necrosis Factor (TNF) Antagonists Sales by Region: 2026-2031
5.3 Global Tumor Necrosis Factor (TNF) Antagonists Revenue by Region: 2020-2031
5.3.1 Global Tumor Necrosis Factor (TNF) Antagonists Revenue by Region: 2020-2025
5.3.2 Global Tumor Necrosis Factor (TNF) Antagonists Revenue by Region: 2026-2031
5.4 North America Tumor Necrosis Factor (TNF) Antagonists Market Facts & Figures by Country
5.4.1 North America Tumor Necrosis Factor (TNF) Antagonists Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Tumor Necrosis Factor (TNF) Antagonists Sales by Country (2020-2031)
5.4.3 North America Tumor Necrosis Factor (TNF) Antagonists Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.4.6 Mexico
5.5 Europe Tumor Necrosis Factor (TNF) Antagonists Market Facts & Figures by Country
5.5.1 Europe Tumor Necrosis Factor (TNF) Antagonists Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Tumor Necrosis Factor (TNF) Antagonists Sales by Country (2020-2031)
5.5.3 Europe Tumor Necrosis Factor (TNF) Antagonists Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.5.9 Spain
5.5.10 Netherlands
5.5.11 Switzerland
5.5.12 Sweden
5.5.13 Poland
5.6 Asia Pacific Tumor Necrosis Factor (TNF) Antagonists Market Facts & Figures by Country
5.6.1 Asia Pacific Tumor Necrosis Factor (TNF) Antagonists Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Tumor Necrosis Factor (TNF) Antagonists Sales by Country (2020-2031)
5.6.3 Asia Pacific Tumor Necrosis Factor (TNF) Antagonists Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 Taiwan
5.6.10 Southeast Asia
5.7 South America Tumor Necrosis Factor (TNF) Antagonists Market Facts & Figures by Country
5.7.1 South America Tumor Necrosis Factor (TNF) Antagonists Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Tumor Necrosis Factor (TNF) Antagonists Sales by Country (2020-2031)
5.7.3 South America Tumor Necrosis Factor (TNF) Antagonists Revenue by Country (2020-2031)
5.7.4 Brazil
5.7.5 Argentina
5.7.6 Chile
5.7.7 Colombia
5.8 Middle East and Africa Tumor Necrosis Factor (TNF) Antagonists Market Facts & Figures by Country
5.8.1 Middle East and Africa Tumor Necrosis Factor (TNF) Antagonists Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Tumor Necrosis Factor (TNF) Antagonists Sales by Country (2020-2031)
5.8.3 Middle East and Africa Tumor Necrosis Factor (TNF) Antagonists Revenue by Country (2020-2031)
5.8.4 Egypt
5.8.5 South Africa
5.8.6 Israel
5.8.7 Türkiye
5.8.8 GCC Countries
6 Segment by Type
6.1 Global Tumor Necrosis Factor (TNF) Antagonists Sales by Type (2020-2031)
6.1.1 Global Tumor Necrosis Factor (TNF) Antagonists Sales by Type (2020-2031) & (K Units)
6.1.2 Global Tumor Necrosis Factor (TNF) Antagonists Sales Market Share by Type (2020-2031)
6.2 Global Tumor Necrosis Factor (TNF) Antagonists Revenue by Type (2020-2031)
6.2.1 Global Tumor Necrosis Factor (TNF) Antagonists Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Tumor Necrosis Factor (TNF) Antagonists Revenue Market Share by Type (2020-2031)
6.3 Global Tumor Necrosis Factor (TNF) Antagonists Price by Type (2020-2031)
7 Segment by Application
7.1 Global Tumor Necrosis Factor (TNF) Antagonists Sales by Application (2020-2031)
7.1.1 Global Tumor Necrosis Factor (TNF) Antagonists Sales by Application (2020-2031) & (K Units)
7.1.2 Global Tumor Necrosis Factor (TNF) Antagonists Sales Market Share by Application (2020-2031)
7.2 Global Tumor Necrosis Factor (TNF) Antagonists Revenue by Application (2020-2031)
7.2.1 Global Tumor Necrosis Factor (TNF) Antagonists Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Tumor Necrosis Factor (TNF) Antagonists Revenue Market Share by Application (2020-2031)
7.3 Global Tumor Necrosis Factor (TNF) Antagonists Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Tumor Necrosis Factor (TNF) Antagonists Value Chain Analysis
8.1.1 Tumor Necrosis Factor (TNF) Antagonists Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Tumor Necrosis Factor (TNF) Antagonists Production Mode & Process
8.2 Tumor Necrosis Factor (TNF) Antagonists Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Tumor Necrosis Factor (TNF) Antagonists Distributors
8.2.3 Tumor Necrosis Factor (TNF) Antagonists Customers
9 Global Tumor Necrosis Factor (TNF) Antagonists Analyzing Market Dynamics
9.1 Tumor Necrosis Factor (TNF) Antagonists Industry Trends
9.2 Tumor Necrosis Factor (TNF) Antagonists Industry Drivers
9.3 Tumor Necrosis Factor (TNF) Antagonists Industry Opportunities and Challenges
9.4 Tumor Necrosis Factor (TNF) Antagonists Industry Restraints
10 Report Conclusion
11 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.